- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01428895
Femoral Bone Metastases
A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture
Bone is a common site of metastasis for a range of malignancies. Bone metastases have the potential to cause significant morbidity including pain, impairment of ambulation and reduced functional independence. Previous research has shown that pathological fractures are observed in 9 to 29 percent of patients with long bone metastases, and a high proportion of these require surgical intervention to relieve pain and restore function.
The goal of this study is to describe the clinical outcomes of patients with femoral metastases at high risk of pathological fracture. Patients referred for treatment of femoral metastases at high risk of fracture will be followed prospectively after undergoing with surgery (± post-operative radiotherapy), or radiotherapy alone. Patient and disease characteristics, ambulatory status and limb function will be documented before treatment. These Clinical outcomes of participants in each treatment group will be measured 6 weeks after treatment, and 3- and 6 months after enrolment, with particular reference to patient-reported outcomes relating to pain, ambulatory status, limb function and quality of life.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rebecca Wong, MB ChB
- Phone Number: 2126 416 946 4501
- Email: Rebecca.Wong@rmp.uhn.on.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Recruiting
- Mount Sinai Hospital
-
Contact:
- Peter Ferguson, MD
- Phone Number: 8687 416 586-4800
- Email: PFerguson@mtsinai.on.ca
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network, Princess Margaret Hospital
-
Contact:
- Rebecca Wong, MB ChB
- Phone Number: 2126 416 946 4501
- Email: Rebecca.Wong@rmp.uhn.on.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of malignancy other than lymphoma
- Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or more)
- At least 18 years of age
- Able to provide written informed consent
- Able to participate in follow-up
Exclusion Criteria:
- Surgical consultation for the purpose of obtaining a tissue/histological diagnosis only, not for treatment
- Histological diagnosis of lymphoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Surgery Alone
|
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan.
The protocol specific part of the study is completely observational.
This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
|
Active Comparator: Surgery + Radiation Therapy
|
Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan.
The protocol specific part of the study is completely observational.
This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To describe the ambulatory status at 3 months by intervention (surgery ± radiotherapy, and radiotherapy alone group) - Ambulatory status
Time Frame: 6 months
|
Patient will be assessed at baseline, 6 weeks, 3 months and 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To describe patterns of management in patients with femoral metastases at high risk of pathological fracture - Perioperative Morbidity and Mortality for surgical patients; pain score and performance status; QOL
Time Frame: 6 months
|
Patients will be assessed at baseline, 6 weeks, 3 months and 6 months
|
6 months
|
To describe patient and disease characteristics of major management groups (surgery ± radiotherapy, radiotherapy alone due to preference, radiotherapy alone due to co-morbid conditions) - Assessment of lower limb function
Time Frame: 6 months
|
Patient will be assessed at baseline, 6 weeks, 3 months, and 6 months.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rebecca Wong, MB ChB, University Health Network, Princess Margaret Hospital
- Principal Investigator: Peter Ferguson, MD, Mount Sinai Hospital, Canada
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCREB 09-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Palleon Pharmaceuticals, Inc.RecruitingMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
Clinical Trials on Surgery Alone
-
Institut Claudius RegaudBayerRecruiting
-
North Tees and Hartlepool NHS Foundation TrustNewcastle-upon-Tyne Hospitals NHS Trust; Gateshead Health NHS Foundation Trust and other collaboratorsUnknownBreast CancerUnited Kingdom
-
University of CalgaryUnknown
-
AHS Cancer Control AlbertaCross Cancer InstituteCompleted
-
Hospices Civils de LyonCompletedOvarian Cancer | Peritoneal CarcinomaFrance
-
Glaukos CorporationCompletedOpen-angle Glaucoma
-
Hospices Civils de LyonCompletedGastric Cancer | Peritoneal CarcinomatosisFrance
-
Melanoma and Skin Cancer Trials LimitedTrans Tasman Radiation Oncology GroupActive, not recruiting
-
H Francis FarhadiWithdrawnSpinal FracturesUnited States
-
University of Maryland, BaltimoreEdwards LifesciencesCompletedCardiac Surgery | Tricuspid Valve RegurgitationUnited States